Published in TB and Outbreaks Week, April 23rd, 2002
Lymerix had caused controversy in recent years, as patients who argued they were sickened by the vaccine asked the government to restrict sales and also filed numerous lawsuits against maker GlaxoSmithKline.
But after a year of investigation, the U.S. Food and Drug Administration had found no proof that the vaccine was dangerous and thus did not tell the manufacturer to end sales, an agency spokeswoman said.
"The reason is there's just no demand for it," said GlaxoSmithKline spokeswoman Ramona Dubose.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week